Tempest Reports Third Quarter 2024 Financial Results and Provides Business Update
Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class (i) targeted and immune-mediated therapeutics to fight cancer, today reported financial results for the quarter ended September 30,
Vivos Therapeutics Inc. shares jumped more than 270% Wednesday after the medical-device maker got regulatory clearance for removable oral appliances that treat obstructive sleep apnea. The U.S ...
New Medical Codes will Facilitate Billing by Commercial Payers for Vivos CARE Treatment for Obstructive Sleep Apnea in Adults and ChildrenLITTLETON, Colo., Oct. 08, 2024 (GLOBE NEWSWIRE ...
Effective January 1, 2025, these codes will streamline insurance coverage and reimbursement for Vivos’ devices, designed to treat obstructive sleep apnea (OSA) in both adults and children.
New Medical Codes will Facilitate Billing by Commercial Payers for Vivos CARE Treatment for Obstructive Sleep Apnea in Adults and Children LITTLETON, Colo., Oct. 08, 2024 (GLOBE NEWSWIRE) -- ...
Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring ...
Vivos Therapeutics, Inc. is a medical technology ... Its solutions are also offered for patients with mild-to-moderate obstructive sleep apnea (OSA). The company was founded by Gurdev Dave Singh ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback